Navigation Links
Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
Date:1/3/2008

CAMBRIDGE, Mass., Jan. 3 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today the appointment of C. Boyd Clarke as Chairman of the Company's Board of Directors. Mr. Clarke is a senior biotechnology and pharmaceutical executive with a significant record of accomplishment over a 30-year industry career.

"It is a great pleasure to welcome Boyd Clarke as Chairman of our Board of Directors," said Julie A. Olson, PhD, President and Chief Executive Officer at Mersana. "Boyd brings diverse management experience and commercial expertise in areas important to Mersana at our stage of development. His skills complement those of our existing team very well, and we anticipate his strategic leadership will be of considerable value as we advance our pipeline."

Over the past 11 years Mr. Clarke has held the role of Chairman and Chief Executive Officer at several publicly-held biotechnology companies, most recently Neose Technologies. During his four year tenure at Neose, Mr. Clarke led the company from a platform-based discovery operation to a clinical stage development company with multiple product candidates. As President and CEO of Aviron he oversaw the Biological Licensing Application (BLA) submission for the company's lead product and ultimately secured the sale of the vaccine company to MedImmune. He also served as President and CEO of US Bioscience. Mr. Clarke began his pharmaceutical career at Merck, where he held a series of increasingly responsible positions, including President of Pasteur Merieux MSD and Vice President of Merck Vaccines. He holds a Bachelor of Science degree and a Master of Arts degree from the University of Calgary. Mr. Clarke serves on the Board of Directors of QLT, Inc. and Rib-X, and is a past board member of the Biotechnology Industry Association (BIO).

"Mersana's Fleximer(R) technology has the potential to create safer and more efficacious cancer drugs, and the promise of the technology is now being demonstrated in their ongoing clinical studies," stated Boyd Clarke. "I'm excited by the Company's prospects and am looking forward to participating in their continued growth as Chairman."

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert material that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer- camptothecin conjugate, which is currently in Phase 1 clinical trials and several preclinical stage oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.


'/>"/>
SOURCE Mersana Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Flagship Biosciences, the leader ... to its Board of Directors. Dr. Gillett recently retired from Charles River Laboratories ... and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. Gillett joined Charles River ...
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
(Date:5/2/2016)... Ohio (PRWEB) , ... May 02, 2016 , ... ... Designed with its clients in mind, the fresh look and added functionality give ... , “Recent years have seen a dynamic shift in agriculture – from precision ...
(Date:4/29/2016)... ... 29, 2016 , ... Proove Biosciences, Inc ., the ... launch of the Proove Health Foundation . The Foundation is a non-profit ... use of personalized medicine for tackling the nation’s most-pressing healthcare epidemics. As part ...
Breaking Biology Technology:
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
Breaking Biology News(10 mins):